email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Review Article(ISSN: 2638-5945)

Plasma Lysophasphatidic Acid Level: A Diagnostic Tool and Benchmark for Ovarian Cancer Management

Volume 1 - Issue 5

Muhammad Imran Qadir1* and Saima Saadat2

  • Author Information Open or Close
    • 1Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan
    • 2Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan

    *Corresponding author: Muhammad Imran Qadir, Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

Received: May 24, 2018;   Published: May 30, 2018

DOI: 10.32474/OAJOM.2018.01.000122

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphatidic acid (LPA), present in ascitic fluid, motivates the enlargement of malignant ovarian tumors by raising the appearance of vascular endothelial growth factor (VEGF) in ovarian cancer cells. Ovarian cancer cell progress is repressed by alendronate, a nitrogen containing biophosphate which attenuate the establishment of Rho by blocking the mevalonate pathway.

Abstract| Ovarian Cancer| Lysophosphatidic Acid in Ovarian Cancer| Management of Ovarian Carcinoma and Lysophosphatidic Acid| References|